METHODS: The study was a multicenter, randomized, blinded, controlled, phase IIb trial
investigating the efficacy and safety of levetiracetam compared with phenobarbital as a first-line …

Objective No drug is yet approved to treat the core symptoms of autism spectrum disorder (
ASD ). Low‐dose suramin was effective in the maternal immune activation and Fragile X …

Genetic studies of autism spectrum disorder (ASD) have established that de novo duplications
and deletions contribute to risk. However, ascertainment of structural variants (SVs) has …

To evaluate the potential importance in autistic subjects of copy number variants (CNVs)
that alter genes of relevance to bioenergetics, ionic metabolism, and synaptic function, we …

Purpose: Continuous video electroencephalography (cEEG) monitoring is the recommended
gold standard of care for at-risk neonates but is not available in many Neonatal Intensive …

We sought to examine, via Phosphorus-31 magnetic resonance spectroscopy ( 31 P-MRS) in
a case-control design, whether bioenergetic deficits in autism spectrum disorders extend to …

Primary mitochondrial respiratory chain (RC) diseases are heterogeneous in etiology and
manifestations but collectively impair cellular energy metabolism. Mechanism(s) by which RC …

Background: There are no FDA approved therapies for neonatal seizures. Previous studies
demonstrated that phenobarbital (PHB) and phenytoin frequently fail to control seizures. …

Lesch-Nyhan disease (LND) is an inherited metabolic disorder characterized by the
overproduction of uric acid and distinct behavioral, cognitive, and motor abnormalities. The most …

Genetic studies of autism spectrum disorder (ASD) have established that de novo duplications
and deletions contribute to risk. However, ascertainment of structural variants (SVs) has …